478 related articles for article (PubMed ID: 12510800)
21. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
[TBL] [Abstract][Full Text] [Related]
23. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
24. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
[TBL] [Abstract][Full Text] [Related]
25. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
[TBL] [Abstract][Full Text] [Related]
26. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
[TBL] [Abstract][Full Text] [Related]
27. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial.
Landin-Wilhelmsen K; Nilsson A; Bosaeus I; Bengtsson BA
J Bone Miner Res; 2003 Mar; 18(3):393-405. PubMed ID: 12619921
[TBL] [Abstract][Full Text] [Related]
28. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
[TBL] [Abstract][Full Text] [Related]
29. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
[TBL] [Abstract][Full Text] [Related]
31. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
32. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
33. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
Eastell R; Krege JH; Chen P; Glass EV; Reginster JY
Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
[TBL] [Abstract][Full Text] [Related]
34. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
35. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
36. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
[TBL] [Abstract][Full Text] [Related]
37. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
[TBL] [Abstract][Full Text] [Related]
39. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
[TBL] [Abstract][Full Text] [Related]
40. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
